Wegovy Pill Under Review; FDA Lifts Obesity Trial Clinical Hold; SGLT2s and Surgery

(MedPage Today) -- The FDA will decide whether to approve a once-daily, 25 mg oral formulation of semaglutide (Wegovy) by the end of 2025. If approved, it would be the first GLP-1 pill indicated for obesity, said maker Novo Nordisk.
The rate of...